DJIA 16,408.54 -16.31 -0.10%
NASDAQ 4,095.52 0.00 0.00%
S&P 500 1,864.85 2.54 0.14%
market minute promo

CEL-SCI Corp

NYSEMKT: CVM

1.27 -0.01 (-0.78%)

REAL-TIME: Last trade at


company name or ticker

Recent Quotes

CVM $1.27 -0.78%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $1.28
Previous Close $1.28
Daily Range $1.26 - $1.33
52-Week Range $0.53 - $3.09
Market Cap $71.0M
P/E Ratio -2.02
Dividend (Yield) $0.00 (0.0%)
Volume 1,324,869
Average Daily Volume 2,110,239
Current FY EPS $0.00

Sector

Healthcare

Industry

Drugs

CEL-SCI Corp (CVM) Description

The Company engages in the research and development of drugs and vaccines. Its most advanced product, Multikine, manufactured using the Company's proprietary cell culture technologies, is being developed for the treatment of cancer. Website: http://www.cel-sci.com/

News & Commentary Rss Feed

CEL-SCI and Ergomed Sign Co-Development and Profit Sharing Agreement for Multikine In HIV/HPV Co-Inf

Morning Market Losers

Cel-Sci Sees Rapid Enrollment For Phase III Head And Neck Cancer Trial

Insider Buying Is On The Rise In These 4 Rallying Stocks

Morning Gainers for Friday, March 14, 2014

Mid-Day Gainers Mar. 7, 2014: SKUL, SMSI, DLIA, BIG, CVM, KFY, GTAT

Morning Movers for Mar. 7, 2014: SKUL, DLIA, BIG, GTAT, CCRN, FL Moving Higher; NLNK, FEYE, SWY, FCE

Morning Movers for Mar. 7, 2014: SKUL, DLIA, BIG, GTAT, CCRN, FL Moving Higher; NLNK, FEYE, SWY, FCEL Lower

4 Stocks Under $10 Triggering Breakouts

5 Biotech Stocks to Trade in February

Navy CRADA Fast-Tracks Cel-Sci's Immunotherapy For HPV

CEL-SCI Says Navy Okays Commencement of Co.'s Phase I Trial for Treatment of Anal Warts in HIV/HPV

CEL-SCI Says Navy Okays Commencement of Co.'s Phase I Trial for Treatment of Anal Warts in HIV/HPV Co-Infected Patients

See More CVM News...

CVM's Top Competitors

CVM $1.27 (-0.78%)
Current stock: CVM
AMGN $115.46 (-0.07%)
Current stock: AMGN
GILD $70.00 (1.04%)
Current stock: GILD
BIIB $290.54 (-0.32%)
Current stock: BIIB